ACML
MCID: ATY042
MIFTS: 50

Atypical Chronic Myeloid Leukemia (ACML)

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Atypical Chronic Myeloid Leukemia

MalaCards integrated aliases for Atypical Chronic Myeloid Leukemia:

Name: Atypical Chronic Myeloid Leukemia 12 58 36 29 6 15
Leukemia, Myeloid, Chronic, Atypical, Bcr-Abl Negative 44 70
Atypical Chronic Myeloid Leukaemia Bcr-Abl1 Negative 12
Atypical Chronic Myeloid Leukemia Bcr-Abl1 Negative 12
Atypical Chronic Myeloid Leukaemia 12
Subacute Myeloid Leukemia 58
Atypical Cml 12
Acml 12

Characteristics:

Orphanet epidemiological data:

58
atypical chronic myeloid leukemia
Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0060597
KEGG 36 H02412
ICD9CM 34 205.2
MeSH 44 D054438
NCIt 50 C3519
SNOMED-CT 67 128826001
ICD10 32 C92.2
MESH via Orphanet 45 D054438
ICD10 via Orphanet 33 C92.2
UMLS via Orphanet 71 C0349640 C1292772
Orphanet 58 ORPHA98824
UMLS 70 C1292772

Summaries for Atypical Chronic Myeloid Leukemia

KEGG : 36 Atypical chronic myeloid leukemia (aCML) is a rare subtype of myelodysplastic/myeloproliferative neoplasm (MDS/MPN). It is characterized by leukocytosis, granulocytic dysplasia, and typically poor patient outcomes. aCML is dominated by mutations in SETBP1, granulocyte colony-stimulating factor 3 receptor (CSF3R), NRAS and KRAS. In addition to these mutations, other recurrent mutations in a variety of genes including NRAS, IDH2, and CBL have recently been described in aCML at lower frequencies.

MalaCards based summary : Atypical Chronic Myeloid Leukemia, also known as leukemia, myeloid, chronic, atypical, bcr-abl negative, is related to leukemia, chronic myeloid and myeloid leukemia. An important gene associated with Atypical Chronic Myeloid Leukemia is CSF3R (Colony Stimulating Factor 3 Receptor), and among its related pathways/superpathways are Ras signaling pathway and Akt Signaling. The drugs Acyclovir and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A myelodysplastic myeloproliferative neoplasm characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene.

Wikipedia : 73 Atypical chronic myeloid leukemia (aCML) is a type of leukemia. It is a heterogeneous disorder belonging... more...

Related Diseases for Atypical Chronic Myeloid Leukemia

Diseases related to Atypical Chronic Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 leukemia, chronic myeloid 30.7 U2AF1 SETBP1 RUNX1 PDGFRB PDGFRA LUC7L2
2 myeloid leukemia 30.5 U2AF1 TET2 RUNX1 PCM1 JAK2 FLT3
3 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.4 RUNX1 FLT3
4 hypereosinophilic syndrome 30.0 PDGFRB PDGFRA JAK2 FGFR1 ABL1
5 leukemia 29.9 U2AF1 TET2 RUNX1 JAK2 FLT3 FGFR1
6 thrombocytosis 29.8 TET2 JAK2 ASXL1
7 patau syndrome 29.8 U2AF1 SRSF2 FLT3 ASXL1
8 acute leukemia 29.8 SETBP1 RUNX1 JAK2 FLT3 FGFR1 CSF3R
9 chronic neutrophilic leukemia 29.6 U2AF1 SRSF2 SETBP1 LUC7L2 JAK2 CSF3R
10 refractory anemia 29.6 TET2 RUNX1 JAK2 ASXL1
11 deficiency anemia 29.4 U2AF1 LUC7L2 JAK2 FLT3 ABL1
12 myeloproliferative neoplasm 29.2 U2AF1 TET2 RUNX1 PDGFRB PDGFRA MYO18A
13 leukemia, acute lymphoblastic 29.1 U2AF1 RUNX1 PTHLH JAK2 FLT3 FGFR1
14 aplastic anemia 28.9 U2AF1 TET2 RUNX1 LUC7L2 FLT3 CSF3R
15 mastocytosis 28.7 TET2 SRSF2 PDGFRB PDGFRA JAK2 FLT3
16 blood platelet disease 28.7 U2AF1 TET2 RUNX1 LUC7L2 JAK2 FLT3
17 systemic mastocytosis 28.7 TET2 SRSF2 PDGFRB PDGFRA JAK2 FGFR1
18 myelodysplastic syndrome 28.6 U2AF1 TET2 SRSF2 SETBP1 RUNX1 PDGFRB
19 chronic myelomonocytic leukemia 28.4 U2AF1 TET2 SRSF2 SETBP1 RUNX1 PDGFRB
20 juvenile myelomonocytic leukemia 28.4 U2AF1 TET2 SETBP1 RUNX1 PDGFRB PDGFRA
21 leukemia, acute myeloid 27.3 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 RUNX1
22 myelodysplastic/myeloproliferative neoplasm 27.2 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 PDGFRB
23 chronic leukemia 27.1 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 PDGFRB
24 subacute myeloid leukemia 11.5
25 splenomegaly 10.4
26 thrombocytopenia 10.4
27 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.3 RUNX1 FLT3
28 mental retardation, autosomal dominant 29 10.3 SETBP1 ABL1
29 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 10.3 JAK2 ABL1
30 graft-versus-host disease 10.2
31 acute graft versus host disease 10.2
32 chromosomal triplication 10.2
33 hypereosinophilic syndrome, idiopathic 10.2 PDGFRB PDGFRA
34 core binding factor acute myeloid leukemia 10.2 RUNX1 JAK2 FLT3
35 etv6 thrombocytopenia and predisposition to leukemia 10.2 RUNX1 JAK2 FLT3
36 cebpa-associated familial acute myeloid leukemia 10.2 RUNX1 JAK2 FLT3
37 acquired polycythemia 10.2 JAK2 ABL1
38 primary hypereosinophilic syndrome 10.2 PDGFRB PDGFRA FGFR1
39 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.1 PDGFRB PDGFRA FGFR1
40 leukemia, acute lymphoblastic 3 10.1 RUNX1 PDGFRA FLT3 ABL1
41 nail disorder, nonsyndromic congenital, 1 10.1 PDGFRB PDGFRA FGFR1
42 b-lymphoblastic leukemia/lymphoma 10.1 FLT3 FGFR1 ABL1
43 dermatofibrosarcoma protuberans 10.1 PDGFRB PDGFRA ABL1
44 myeloid and lymphoid neoplasms associated with fgfr1 abnormalities 10.1 FLT3 FGFR1
45 lymphoblastic leukemia, acute, with lymphomatous features 10.1 JAK2 FGFR1 ABL1
46 acquired von willebrand syndrome 10.0 U2AF1 JAK2
47 immunodeficiency 21 10.0 LUC7L2 FLT3 ASXL1
48 endomyocardial fibrosis 10.0 PDGFRB PDGFRA
49 large cell carcinoma 10.0 PTHLH PDGFRA FGFR1
50 down syndrome 10.0

Graphical network of the top 20 diseases related to Atypical Chronic Myeloid Leukemia:



Diseases related to Atypical Chronic Myeloid Leukemia

Symptoms & Phenotypes for Atypical Chronic Myeloid Leukemia

GenomeRNAi Phenotypes related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.78 U2AF1
2 Decreased viability GR00173-A 10.78 PDGFRA FLT3
3 Decreased viability GR00221-A-1 10.78 ABL1 ETNK1 PDGFRA PDGFRB FGFR1 FLT3
4 Decreased viability GR00221-A-2 10.78 ABL1 ETNK1 FGFR1 JAK2 RYK
5 Decreased viability GR00221-A-3 10.78 ABL1 ETNK1 PDGFRA PDGFRB
6 Decreased viability GR00221-A-4 10.78 ETNK1 PDGFRA PDGFRB FLT3 RYK
7 Decreased viability GR00249-S 10.78 PDGFRA CSF3R RUNX1
8 Decreased viability GR00342-S-1 10.78 ABL1 ETNK1 PDGFRB RYK
9 Decreased viability GR00342-S-2 10.78 ABL1 RYK
10 Decreased viability GR00342-S-3 10.78 ABL1 RYK
11 Decreased viability GR00386-A-1 10.78 FGFR1 LUC7L2 SRSF2
12 Decreased viability GR00402-S-2 10.78 PDGFRA RUNX1 SRSF2 U2AF1 U2AF1L4
13 Decreased substrate adherent cell growth GR00193-A-2 9.46 ABL1
14 Decreased substrate adherent cell growth GR00193-A-4 9.46 ABL1 FGFR1 FLT3
15 Decreased cell viability after pRB stimulation GR00230-A-1 8.96 PDGFRB
16 Increased viability GR00386-A-1 8.32 ABL1

MGI Mouse Phenotypes related to Atypical Chronic Myeloid Leukemia:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.3 ABL1 ASXL1 CSF3R FGFR1 JAK2 PCM1
2 cardiovascular system MP:0005385 10.29 ABL1 FGFR1 JAK2 MYO18A PCM1 PDGFRA
3 cellular MP:0005384 10.27 ABL1 ASXL1 CSF3R FGFR1 FLT3 JAK2
4 growth/size/body region MP:0005378 10.22 ABL1 ASXL1 FGFR1 FLT3 JAK2 MYO18A
5 hematopoietic system MP:0005397 10.21 ABL1 ASXL1 CSF3R ETNK1 FGFR1 FLT3
6 immune system MP:0005387 10.2 ABL1 ASXL1 CSF3R ETNK1 FGFR1 FLT3
7 endocrine/exocrine gland MP:0005379 10.17 ABL1 ASXL1 FGFR1 FLT3 JAK2 PDGFRA
8 mortality/aging MP:0010768 10.16 ABL1 ASXL1 CSF3R FGFR1 FLT3 JAK2
9 craniofacial MP:0005382 10.13 ABL1 ASXL1 FGFR1 MYO18A PCM1 PDGFRA
10 digestive/alimentary MP:0005381 10 ABL1 ASXL1 FGFR1 PDGFRA PDGFRB PTHLH
11 neoplasm MP:0002006 9.7 ASXL1 FLT3 JAK2 PDGFRA PTHLH RUNX1
12 normal MP:0002873 9.56 ABL1 FGFR1 JAK2 PDGFRA PDGFRB PTHLH
13 skeleton MP:0005390 9.4 ABL1 ASXL1 ETNK1 FGFR1 FLT3 JAK2

Drugs & Therapeutics for Atypical Chronic Myeloid Leukemia

Drugs for Atypical Chronic Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acyclovir Approved Phase 3 59277-89-3 2022
2
Mycophenolic acid Approved Phase 3 24280-93-1 446541
3 valacyclovir Phase 3
4 Antibiotics, Antitubercular Phase 3
5 Anti-Infective Agents Phase 3
6 Anti-Bacterial Agents Phase 3
7 Antitubercular Agents Phase 3
8
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
9
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
11
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
12
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
13
alemtuzumab Approved, Investigational Phase 2 216503-57-0
14
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
15
Cyproheptadine Approved Phase 2 129-03-3 2913
16
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
17
Carmustine Approved, Investigational Phase 2 154-93-8 2578
18
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
19
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
20
Etanercept Approved, Investigational Phase 2 185243-69-0
21
Ondansetron Approved Phase 2 99614-02-5 4595
22
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
23
Venetoclax Approved, Investigational Phase 1, Phase 2 1257044-40-8 49846579
24
Melphalan Approved Phase 2 148-82-3 4053 460612
25
Etoposide Approved Phase 2 33419-42-0 36462
26
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
27
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
28
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
29
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
30
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
31
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
32
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
33
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
34
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
35
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
36
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
37
Mesna Approved, Investigational Phase 2 3375-50-6 598
38
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
39
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
40
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
41
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
42
Iron Approved Phase 2 7439-89-6 23925 29936
43
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381 214348
44
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
45
tipifarnib Investigational Phase 1, Phase 2 192185-72-1 159324
46
Pevonedistat Investigational Phase 1, Phase 2 905579-51-3
47
Veliparib Investigational Phase 2 912444-00-9 11960529
48
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
49
Molgramostim Investigational Phase 2 99283-10-0
50 Flt3 ligand protein Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
2 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
3 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
4 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
5 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
6 Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R Completed NCT02092324 Phase 2 Ruxolitinib Phosphate
7 Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial Completed NCT00397813 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
8 A Phase II Study to Evaluate Efficacy and Tolerability of Methotrexate in Combination With Glucocorticoids for the Treatment of Newly Diagnosed Acute Graft-Versus-Host Disease After Nonmyeloablative Hematopoietic Cell Transplantation Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
9 A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
10 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
11 Ex Vivo Expanded Megakaryocytes for Supportive Care of Breast Cancer Patients: A Phase I/II Study Completed NCT00006225 Phase 1, Phase 2
12 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With Severe Aplastic Anemia, Inborn Errors in Metabolism, or Inherited Hematologic Stem Cell Disorders Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
13 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With High Risk Hematologic Malignancies Completed NCT00003335 Phase 2 busulfan;cyclosporine;melphalan;methylprednisolone
14 A Phase II Trial of Combination Therapy With Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients With Chronic Idiopathic Myelofibrosis or Overlap Myelodysplastic/Myeloproliferative Disorders Completed NCT00274820 Phase 2 arsenic trioxide;dexamethasone;thalidomide
15 Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
16 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
17 Autologous Blood and Marrow Transplantation for Hematologic Malignancy and Selected Solid Tumors Completed NCT00060255 Phase 2 busulfan;carboplatin;carmustine;cyclophosphamide;etoposide;melphalan;thiotepa
18 A Pilot Study Of Cytarabine And High-Dose Mitoxantrone For Relapsed Or Refractory Hematologic Malignancies Completed NCT00047021 Phase 2 cytarabine;mitoxantrone hydrochloride
19 A Multicenter Study of Unrelated Umbilical Cord Blood as an Alternate Source of Stem Cells for Transplantation Completed NCT00003913 Phase 2 busulfan;cyclophosphamide;methylprednisolone
20 Allogeneic Peripheral Blood Progenitor Cell Transplantation Using Histocompatible Sibling-Matched Donor Cells After High-Dose Busulfan/Cyclophosphamide as Therapy for Hematologic Malignancies Completed NCT00003116 Phase 2 busulfan;cyclophosphamide;cyclosporine
21 Unrelated Bone Marrow Transplantation With Cyclophosphamide and Total Body Irradiation For Hematologic Malignancies and Bone Marrow Failure States Completed NCT00002809 Phase 2 cyclophosphamide;methotrexate;tacrolimus
22 ALLOGENEIC MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR AGNOGENIC MYELOID METAPLASIA WITH MYELOFIBROSIS Completed NCT00002792 Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate;tacrolimus
23 A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease Completed NCT00410657 Phase 2 methylprednisolone;prednisone
24 Conditioning For Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
25 Therapy of Early Stage Myelodysplastic Syndrome (MDS) With ATG and Etanercept Completed NCT00217386 Phase 2
26 A Phase I/II Study of Sirolimus in Addition to Tacrolimus and Methotrexate for the Prevention of Acute-Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation From Unrelated Donors Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
27 Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation Completed NCT00055653 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;melphalan;methylprednisolone
28 Phase II Study of Doxercalciferol for the Treatment of Myelodysplastic Syndromes Completed NCT00052832 Phase 2
29 Non-Myeloablative Allogeneic Hematopoietic Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies and Disorders Completed NCT00053989 Phase 2 cyclophosphamide;fludarabine phosphate;methylprednisolone;mycophenolate mofetil;tacrolimus
30 Low Dose Total-Body Irradiation And Fludarabine Followed By HLA Matched Allogeneic Stem Cell Transplantation For Hematologic Malgnancies - A Multi-Center Study Completed NCT00044954 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
31 Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study Completed NCT00004899 Phase 2 busulfan;etoposide
32 Phase II Study of High-Dose Busulfan and Cyclophosphamide Followed by Allogeneic Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia Completed NCT00004896 Phase 2 busulfan;cyclophosphamide
33 A Phase II Study of the Combination of Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-Versus-Host Disease Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
34 Therapy of Advanced Stage Myelodysplastic Syndrome (MDS) With Arsenic Trioxide Given in Combination With Etanercept: A Phase I/II Study Completed NCT00093366 Phase 1, Phase 2 arsenic trioxide
35 Hematopoietic Stem Cell Transplantation Using Bone Marrow Or Peripheral Blood Stem Cells From Matched, Unrelated, Volunteer Donors Completed NCT00054327 Phase 2 busulfan;cyclophosphamide;cytarabine;Etoposide
36 A Phase I/II Study of Immunologically Engineered rhG-CSF Mobilized Peripheral Blood Stem Cells (PBSC) for Allogeneic Transplant From HLA Identical, Related Donors for Treatment of Myeloid Malignancies Completed NCT00049634 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
37 Phase II Study of Fludarabine, Carboplatin, and Topotecan With Thalidomide for Patients With Relapsed/Refractory or High Risk Acute Myelogenous Leukemia, Chronic Myeloid Leukemia and Advanced Myelodysplastic Syndromes Completed NCT00053287 Phase 2 carboplatin;fludarabine phosphate;thalidomide;topotecan hydrochloride
38 Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) After T-Lymphocyte Depleted Allogeneic BMT for Myelodysplastic Syndromes Completed NCT00003961 Phase 2
39 Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation With a Conditioning Regimen of Targeted Busulfan, Cyclophosphamide, and Thymoglobulin Completed NCT00611351 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
40 Phase II Trial of Triapine (NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC) Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
41 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
42 A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial Completed NCT00105001 Phase 2 Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
43 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
44 Phase I/II Study of Tipifarnib [Zarnestra, Farnesyltransferase Inhibitor R115777 (NSC 702818)] in Patients With Myeloproliferative Disorders Completed NCT02210858 Phase 1, Phase 2 Tipifarnib
45 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
46 Phase II Study of a Geriatric Assessment-Driven, Risk-Adapted Allogeneic Hematopoietic Cell Transplant Strategy for Older Patients With Myelodysplastic Syndrome, Myeloproliferative Neoplasms, and Related Blood Disorders Recruiting NCT04761770 Phase 2 conditioning regimen
47 A Phase I/II Study of Azacitidine, Venetoclax and Pevonedistat in Adults With Newly Diagnosed Secondary or Therapy-Related AML Recruiting NCT03862157 Phase 1, Phase 2 Azacitidine;Pevonedistat;Venetoclax
48 A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders Active, not recruiting NCT00544115 Phase 2 busulfan;cyclophosphamide;cyclosporine;etoposide;fludarabine phosphate;melphalan;methotrexate;mycophenolate mofetil;sirolimus;tacrolimus
49 NCI 10147: A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML) Suspended NCT03289910 Phase 2 Carboplatin;Topotecan;Topotecan Hydrochloride;Veliparib
50 A Phase II Study of VEGF Trap (NSC 724770) in Patients With MDS Terminated NCT00509249 Phase 2

Search NIH Clinical Center for Atypical Chronic Myeloid Leukemia

Cochrane evidence based reviews: leukemia, myeloid, chronic, atypical, bcr-abl negative

Genetic Tests for Atypical Chronic Myeloid Leukemia

Genetic tests related to Atypical Chronic Myeloid Leukemia:

# Genetic test Affiliating Genes
1 Atypical Chronic Myeloid Leukemia 29

Anatomical Context for Atypical Chronic Myeloid Leukemia

MalaCards organs/tissues related to Atypical Chronic Myeloid Leukemia:

40
Myeloid, Bone, Bone Marrow, Neutrophil, Liver, Nk Cells, Endothelial

Publications for Atypical Chronic Myeloid Leukemia

Articles related to Atypical Chronic Myeloid Leukemia:

(show top 50) (show all 162)
# Title Authors PMID Year
1
A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. 61 6
17764812 2007
2
A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. 6
29025582 2017
3
A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3? 6
27795560 2017
4
Multiple MYO18A-PDGFRB fusion transcripts in a myeloproliferative neoplasm patient with t(5;17)(q32;q11). 6
28261327 2017
5
A three-way translocation of MLL, MLLT11, and the novel reciprocal partner gene MYO18A in a child with acute myeloid leukemia. 6
22682626 2012
6
The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. 6
15800673 2005
7
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review. 61
33275673 2020
8
Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. 61
33275756 2020
9
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. 61
33196013 2020
10
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. 61
32573691 2020
11
Molecular genetics of MDS/MPN overlap syndromes. 61
33038984 2020
12
Atypical Chronic Myeloid Leukemia: Where Are We Now? 61
32962122 2020
13
Defective migration and dysmorphology of neutrophil granulocytes in atypical chronic myeloid leukemia treated with ruxolitinib. 61
32660441 2020
14
Accelerated Phase of Atypical Chronic Myeloid Leukemia with Severe Disseminated Intravascular Coagulation at Initial Presentation. 61
32188810 2020
15
Atypical CML- the role of morphology and precision genomics. 61
32460981 2020
16
A 19-year-old patient with atypical chronic myeloid leukemia. 61
32193626 2020
17
Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation. 61
31439673 2020
18
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. 61
31880950 2020
19
Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. 61
31904665 2020
20
Systemic mastocytosis with associated BCRABL1-negative atypical chronic myeloid leukemia. 61
31807857 2020
21
Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia. 61
31692115 2020
22
A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant JAK2 V617F and SETBP1 mutations: a case report and literature review. 61
32782768 2020
23
[Mediastinal abscess due to Aspergillus in a patient with atypical chronic myeloid leukemia, BCR-ABL1-negative]. 61
32147612 2020
24
Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis. 61
33117717 2020
25
CSF3R truncation mutations in a patient with B-cell acute lymphoblastic leukemia and a favorable response to chemotherapy plus dasatinib. 61
32577374 2020
26
Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene. 61
31327842 2019
27
Testicular involvement without testicular enlargement in a young male with atypical chronic myeloid leukemia. 61
31276287 2019
28
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL). 61
31102420 2019
29
Atypical chronic myeloid leukemia achieving good response with azacitidine. 61
31607707 2019
30
Characteristics and survival of patients with atypical chronic myeloid leukemia. 61
31730680 2019
31
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. 61
30819912 2019
32
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. 61
31366621 2019
33
Myeloproliferative neoplasms: Diagnostic workup of the cythemic patient. 61
31069979 2019
34
Pulmonary alveolar proteinosis developing during steroid treatment in a patient with organizing pneumonia in association with atypical chronic myeloid leukemia. 61
30899476 2019
35
Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. 61
30635983 2019
36
The mutational landscape of atypical chronic myeloid leukemia. 61
31217789 2019
37
Atypical chronic myeloid leukemia BCR-ABL 1 negative: A case report and literature review. 61
31194134 2019
38
Current and evolving understanding of atypical chronic myeloid leukemia. 61
30078497 2019
39
[MYC gene amplification attributed to double minutes in a patient with atypical chronic myeloid leukemia]. 61
31839631 2019
40
Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia. 61
31112981 2019
41
Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). 61
30555034 2019
42
Two myeloid leukemia cases with rare FLT3 fusions. 61
30559310 2018
43
Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan. 61
30458320 2018
44
Sudden Intracranial Hemorrhage in a Patient With Atypical Chronic Myeloid Leukemia in Chronic Phase. 61
29227326 2018
45
Clinical Utility of Classical and Nonclassical Monocyte Percentage in the Diagnosis of Chronic Myelomonocytic Leukemia. 61
29982327 2018
46
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. 61
29875417 2018
47
A typical atypical chronic myeloid leukemia. 61
29744086 2018
48
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. 61
29468060 2018
49
Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. 61
29455651 2018
50
Atypical chronic myeloid leukemia: a rare entity with management challenges. 61
29226717 2018

Variations for Atypical Chronic Myeloid Leukemia

ClinVar genetic disease variations for Atypical Chronic Myeloid Leukemia:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FLT3 , MYO18A t(13;17)(q12.2;q11.2) Translocation Likely pathogenic 590265 GRCh37: 17:27423778-27423779
GRCh38:

Expression for Atypical Chronic Myeloid Leukemia

Search GEO for disease gene expression data for Atypical Chronic Myeloid Leukemia.

Pathways for Atypical Chronic Myeloid Leukemia

Pathways related to Atypical Chronic Myeloid Leukemia according to KEGG:

36
# Name Kegg Source Accession
1 Ras signaling pathway hsa04014

Pathways related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.26 RYK PDGFRB PDGFRA JAK2 FLT3 FGFR1
2
Show member pathways
12.77 RYK PDGFRB PDGFRA FLT3 FGFR1
3
Show member pathways
12.77 PDGFRB PDGFRA JAK2 FLT3 FGFR1 CSF3R
4
Show member pathways
12.55 RUNX1 PDGFRB PDGFRA FLT3 FGFR1 ABL1
5
Show member pathways
12.52 PDGFRB PDGFRA FLT3 FGFR1 ABL1
6 12.28 RUNX1 PDGFRB PDGFRA JAK2 FLT3 FGFR1
7
Show member pathways
12.22 PDGFRB PDGFRA JAK2 CSF3R
8
Show member pathways
12.19 RYK PDGFRB PDGFRA FLT3 FGFR1
9
Show member pathways
12.07 PDGFRB PDGFRA FGFR1 CSF3R
10 11.67 PDGFRB PDGFRA FGFR1
11
Show member pathways
11.61 PDGFRB FLT3 FGFR1
12
Show member pathways
11.32 PDGFRB PDGFRA ABL1
13 11.3 PDGFRB PDGFRA FLT3 FGFR1
14 11.27 PDGFRB PDGFRA JAK2 FLT3 FGFR1 ABL1
15 11.23 PDGFRB PDGFRA FGFR1
16 11.18 PDGFRB PDGFRA FGFR1
17
Show member pathways
10.96 PDGFRB PDGFRA FLT3
18 10.86 RYK PDGFRB PDGFRA FLT3 FGFR1
19 10.72 PDGFRB PDGFRA

GO Terms for Atypical Chronic Myeloid Leukemia

Cellular components related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 10 U2AF1L4 U2AF1 SRSF2 SETBP1 RUNX1 PTHLH
2 nucleus GO:0005634 9.86 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 RYK
3 U2AF GO:0089701 9.16 U2AF1L4 U2AF1
4 receptor complex GO:0043235 9.1 RYK PDGFRB PDGFRA FLT3 FGFR1 CSF3R

Biological processes related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.01 PTHLH PDGFRB PDGFRA JAK2 FLT3 FGFR1
2 protein phosphorylation GO:0006468 10 RYK PDGFRB PDGFRA JAK2 FLT3 FGFR1
3 phosphorylation GO:0016310 9.97 RYK PDGFRB PDGFRA JAK2 FLT3 FGFR1
4 cell migration GO:0016477 9.92 PDGFRB PDGFRA MYO18A FGFR1
5 MAPK cascade GO:0000165 9.88 PDGFRB PDGFRA JAK2 FLT3 FGFR1
6 mRNA export from nucleus GO:0006406 9.81 U2AF1L4 U2AF1 SRSF2
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.8 RYK PDGFRB PDGFRA FLT3 FGFR1
8 hemopoiesis GO:0030097 9.78 RUNX1 FLT3 ASXL1
9 positive regulation of MAP kinase activity GO:0043406 9.77 PDGFRB FLT3 FGFR1
10 mRNA 3'-end processing GO:0031124 9.76 U2AF1L4 U2AF1 SRSF2
11 RNA export from nucleus GO:0006405 9.75 U2AF1L4 U2AF1 SRSF2
12 phosphatidylinositol-mediated signaling GO:0048015 9.74 PDGFRB PDGFRA FGFR1
13 skeletal system morphogenesis GO:0048705 9.72 RYK PDGFRA FGFR1
14 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.67 PDGFRB PDGFRA FLT3
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.65 PDGFRB PDGFRA JAK2 FLT3 FGFR1
16 negative regulation of cell-cell adhesion GO:0022408 9.64 JAK2 ABL1
17 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.63 PDGFRB JAK2
18 protein autophosphorylation GO:0046777 9.63 PDGFRB PDGFRA JAK2 FLT3 FGFR1 ABL1
19 regulation of myeloid cell differentiation GO:0045637 9.62 RUNX1 CSF3R
20 platelet-derived growth factor receptor signaling pathway GO:0048008 9.62 PDGFRB PDGFRA JAK2 ABL1
21 cardiac myofibril assembly GO:0055003 9.61 PDGFRB PDGFRA
22 positive regulation of phospholipase C activity GO:0010863 9.61 PDGFRB PDGFRA FGFR1
23 retina vasculature development in camera-type eye GO:0061298 9.6 PDGFRB PDGFRA
24 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.56 PDGFRB ABL1
25 metanephric glomerular capillary formation GO:0072277 9.52 PDGFRB PDGFRA
26 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.51 PDGFRB PDGFRA
27 positive regulation of kinase activity GO:0033674 9.35 RYK PDGFRB PDGFRA FLT3 FGFR1
28 peptidyl-tyrosine phosphorylation GO:0018108 9.17 RYK PDGFRB PDGFRA JAK2 FLT3 FGFR1

Molecular functions related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.51 U2AF1 TET2 SRSF2 SETBP1 RYK RUNX1
2 transferase activity GO:0016740 10.13 RYK PDGFRB PDGFRA JAK2 FLT3 FGFR1
3 nucleotide binding GO:0000166 10.02 RYK PDGFRB PDGFRA MYO18A JAK2 FLT3
4 ATP binding GO:0005524 9.96 RYK RUNX1 PDGFRB PDGFRA MYO18A JAK2
5 protein kinase activity GO:0004672 9.87 RYK PDGFRB PDGFRA JAK2 FLT3 FGFR1
6 kinase activity GO:0016301 9.76 RYK PDGFRB PDGFRA JAK2 FLT3 FGFR1
7 growth factor binding GO:0019838 9.58 PDGFRB PDGFRA FLT3
8 platelet-derived growth factor receptor binding GO:0005161 9.55 PDGFRB PDGFRA
9 platelet-derived growth factor binding GO:0048407 9.51 PDGFRB PDGFRA
10 peptide hormone receptor binding GO:0051428 9.49 PTHLH JAK2
11 pre-mRNA 3'-splice site binding GO:0030628 9.48 U2AF1L4 U2AF1
12 vascular endothelial growth factor-activated receptor activity GO:0005021 9.46 PDGFRA FLT3
13 vascular endothelial growth factor binding GO:0038085 9.43 PDGFRB PDGFRA
14 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.35 RYK PDGFRB PDGFRA FLT3 FGFR1
15 protein tyrosine kinase activity GO:0004713 9.17 RYK PDGFRB PDGFRA JAK2 FLT3 FGFR1

Sources for Atypical Chronic Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....